You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Medtronic
Merck
Boehringer Ingelheim
Johnson and Johnson

Last Updated: October 26, 2020

DrugPatentWatch Database Preview

Details for Patent: 8,748,425

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,748,425 protect, and when does it expire?

Patent 8,748,425 protects COMBIGAN and is included in one NDA.

This patent has twenty-six patent family members in nineteen countries.

Summary for Patent: 8,748,425
Title:Combination of brimonidine and timolol for topical ophthalmic use
Abstract: Disclosed are pharmaceutical compositions comprising brimondine and timolol for topical ophthalmic delivery and a method of treatment comprising administering said composition when indicated for glaucoma and associated conditions such as elevated intraocular pressure in the eyes of humans.
Inventor(s): Chang; Chin-Ming (Tustin, CA), Beck; Gary J. (Fullerton, CA), Pratt; Cynthia C. (Mission Viejo, CA), Batoosingh; Amy L. (Mission Viejo, CA)
Assignee: Allergan Sales, LLC (Irvine, CA)
Application Number:13/957,287
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,748,425
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 8,748,425

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Allergan COMBIGAN brimonidine tartrate; timolol maleate SOLUTION/DROPS;OPHTHALMIC 021398-001 Oct 30, 2007 RX Yes Yes   Start Trial   Start Trial Y REDUCTION OF ELEVATED INTRAOCULAR PRESSURE   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,748,425

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2003228480   Start Trial
Brazil 0302584   Start Trial
Canada 2440764   Start Trial
China 100558364   Start Trial
China 101664414   Start Trial
China 1516588   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
McKesson
Express Scripts
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.